Sacituzumab Govitecan

Molecule Name: Sacituzumab Govitecan
Active Ingredient: Sacituzumab govitecan
Dosage Form: 200mg
Manufacturer Name:

Adult patients with triple-negative breast cancer are treated with the cancer drug Sacituzumab govitecan. When surgical removal of the cancer is not possible because it has spread to nearby tissues or to the body as a whole (locally progressed cancer), this treatment is used (metastatic ). It is prescribed to patients who have undergone two or more systemic (whole-body) therapies in the past, at least one of which was for an advanced illness.

website background

How Darzalex faspro can benefit people?

Darzalex or Darzalex Faspro has been studied in both newly diagnosed and relapsed/refractory multiple myeloma patients. Darzalex/Darzalex Faspro studies in myeloma patients have included the mentioned patient populations:

  • Patients who have previously received multiple therapies (heavily pre-treated)
  • Patients with impaired renal function (renal impairment)
  • Patients who are not candidates for stem cell transplantation
  • Patients who had failed both PIs and IMiDs
  • Patients who have mildly impaired liver function (mild hepatic impairment)

Mechanism of Working

In myeloma cells, the drug Darzalex Faspro interacts to the protein CD38 (this protein is also found on other cells, such as red blood cells). It is believed to reduce the growth of myeloma cells in a number of ways, including by assisting the immune system in finding and eliminating myeloma cells.

A monoclonal antibody called Darzalex can be given to patients in one of two ways: either as an intravenous (IV) infusion or as a subcutaneous (SC) injection (that is, under the skin).

What could be the possible side effects of Darzalex Faspro?

When a patient has an adverse reaction to an infusion, their Darzalex Faspro infusion is stopped, and their symptoms are handled. The infusion may be restarted at a slower rate after the symptoms go away. Those who have several severe responses or a life-threatening infusion reaction stop using Darzalex.

Low neutrophil, platelet, lymphocyte, red blood cell, and haemoglobin counts are the most frequent significant adverse effects. Other issues include:

About Us

HAYAT ALHIKMAH, a pharmaceutical consultant in Dubai, is here to assist you in fulfilling all your medical requirements. We can assist in procuring medicines like Sacituzumab Govitecan. We offer quality assurance.

We have a strong commitment to consult in availing the highest-quality pharmaceuticals and medications. Our team is here to help you every step of the way and make sure that your requirements get fulfilled as soon as possible. Our team of specialists are extremely skilled and knowledgeable about various medications. 

0 +


0 +

Ware House

0 +



Those who have had a serious allergic reaction to Sacituzumab Govitecan should not take it. Moreover, Sacituzumab Govitecan should not be taken by women who are pregnant or breastfeeding.

Several individuals in the clinical trial who received Sacituzumab Govitecan lived almost two times as long as those who received conventional chemotherapy. This outcome, known as median overall survival (OS), represents the amount of time that half of the population has survived since receiving therapy.

A cancer drug called SN-38 is a member of the class of drugs known as “topoisomerase inhibitors.” Topoisomerase I, an enzyme involved in copying cell DNA required for the production of new cells, is blocked by this substance. Cancer cells are prevented from proliferating and ultimately dying by inhibiting the enzyme.

Only a prescription is required to buy the medication. It needs to be recommended and administered by a medical expert with knowledge of the use of cancer medications. If patients experience serious allergic responses, it should be issued in an area with resuscitation tools on hand.

Sacituzumab Govitecan solution infusion bags can be kept refrigerated at 2°C to 8°C, away from light, for up to 24 hours.

A prescription drug called Sacituzumab Govitecan is used to treat breast cancer and urothelial cancer symptoms. Sacituzumab Govitecan can be taken either on its own or with other drugs. On Days 1 and 8 of the 21-day therapy cycles, an intravenous infusion of 10 mg/kg of Sacituzumab Govitecan is advised as the recommended dose. Until the disease becomes worse or the side effects become intolerable, keep on treating. Sacituzumab Govitecan should not be given at levels higher than 10 mg/kg.

The most frequent adverse effects of Sacituzumab Govitecan are decreased red blood cell and white blood cell counts, fatigue or weakness, hair loss, constipation, elevated blood sugar levels, decreased blood protein levels, and decreased appetite.